Phio Pharmaceuticals Q1 net loss widens on higher R&D costs

Phio Pharmaceuticals

07/05/2026 21:57

Overview

US siRNA cancer drug developer's Q1 net loss widened on higher R&D and admin expenses

Company completed clinical phase of PH-762 Phase 1b skin cancer trial; final data pending analysis

Cash position fell to $17 mln; management says cash runway extended into H1 2027

Outlook

Company anticipates research and development expenses will continue to increase

Phio expects its cash runway to extend into the first half of 2027

Result Drivers

R&D SPENDING - Research and development expenses rose sharply due to clinical trial, chemistry, manufacturing and toxicology costs for PH-762

ADMIN COSTS - General and administrative expenses increased mainly from employee-related costs, investor outreach and professional fees

Company press release: ID:nNFC3snJJK

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Net Income
-$4.003 mln
Q1 Operating Expenses
$4.17 mln
Q1 Operating Income
-$4.17 mln


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)